In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer. ★ Support this podcast ★
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from GOG GYN-LIVE
GOG-3073/ ENGOT-ov72/ APGOT-Ov10/ LACOG-0223/ ROSELLA FDA APPROVAL PODCAST
InnovaTV 205 GOG-3024/ENGOT-cx8 Publication Podcast
Uterine Cancer Awareness Month 2026 Podcast
Accrual Culture: Top Points for Site Selection - Timelines
Get summaries like this every morning.
Free AI-powered recaps of GOG GYN-LIVE and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.